Sorafenib, a small-molecule antitumour drug that acts by inhibiting angiogenesis and tumour growth, is widely used in unresectable or metastatic HCC.3,4 We found that Galectin-3 knockdown remarkably enhanced the inhibitory effect of sorafenib on HCC cell (Huh7) proliferation in the colony formation and CCK8 assays, which was disrupted by β-catenin overexpression (Fig. 5a, c). Here, LGALS3 is linked to neoplasm.